Abstract:
The present disclosure provides methods for enabling an individual having a cat allergy to have a cat as a pet. Such a method can include quantitatively determining a threshold in the individual for an environmental level of an allergen produced by the cat and selecting a cat or a breed of cat that creates an environmental level of the allergen that is less than the threshold. Additionally, such a method can include lowering the allergens disseminated by the cat by treating the environment inhabited by the cat during a time period where the cat expresses elevated allergens.
Abstract:
The invention provides methods for determining if an animal's metabolism has been shifted to ketogenic status by collecting a first urine sample from the animal when the animal's metabolism is not in a ketogenic status; collecting a second urine sample from the animal when the animal's metabolism is possibly in a ketogenic status; analyzing the first urine sample and the second urine sample for beta-hydroxy butyrate; and determining that the animal's metabolism has been shifted to ketogenic status if the concentration of beta-hydroxy butyrate in the second urine sample exceeds the concentration of beta-hydroxy butyrate in the first urine sample by ten percent (10%) or more.
Abstract:
The present disclosure provides methods for enabling an individual having a cat allergy to have a cat as a pet. Such a method can include quantitatively determining a threshold in the individual for an environmental level of an allergen produced by the cat and selecting a cat or a breed of cat that creates an environmental level of the allergen that is less than the threshold. Additionally, such a method can include lowering the allergens disseminated by the cat by treating the environment inhabited by the cat during a time period where the cat expresses elevated allergens.
Abstract:
Formulations, compositions and products for reducing allergenic Fel d 1 from the environment are disclosed. The formulations include at least one protease that interacts with the Fel d 1 and substantially degrades allergenic epitopes on the Fel d 1. Methods of using the formulations for reducing or eliminating allergenic Fel d 1 from the environment are also disclosed.
Abstract translation:公开了用于降低环境中致敏性Fel d 1的制剂,组合物和产品。 该制剂包括与Fel d 1相互作用的至少一种蛋白酶,并且在Fel d 1上基本上降解过敏表位。还公开了使用该制剂减少或消除来自环境的过敏性Fel d 1的方法。